CRBU
Caribou Biosciences, Inc.
Next earnings Aug 4, 2026 · consensus $-0.32 EPS, $2.32M rev
Last earnings -3.6% on 2026-05-07
$1.68
▲ +7.01%$1.68▲ +33.33%
over 1Y
L $1.25EODHDH $2.84
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+7.0%
1W+7.0%
1M-27.3%
3M-5.6%
YTD+5.7%
1Y+33.3%
Sell
Conviction
Horizon
Medium (3–12mo)
Street · 14 analysts
Buy
Revenue grew 11.7% YoY; but unprofitable (net margin -1327.4%).
Revenue (FY2025) $11.2M · FY2025
Caribou Biosciences, Inc. shows $11.2M in FY2025 revenue (+11.7% YoY), a -1327.4% net margin, and -121.2% ROE.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $9.60M | $13.9M | $34.5M | $9.99M | $11.2M |
| Gross profit | — | — | — | — | — |
| Operating income | -$67.0M | -$106M | -$116M | -$167M | -$148M |
| Net income | -$66.9M | -$99.4M | -$102M | -$149M | -$148M |
| Diluted EPS | -$2.11 | -$1.64 | -$1.38 | -$1.65 | -$1.59 |
| Net margin | -697.3% | -717.8% | -296.1% | -1491.9% | -1327.4% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$150M
EV / EBITDA—
EV / Sales13.4
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-91.2%
FCF yield-69.2%
Quality & risk
ROIC (est.)-95.9%
Free cash flow-$112M
Total debt—
Net cash$12.4M
Altman Z-Score-4.84 distress
Piotroski F-Score2/7
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY+3.9%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsRoutine disclosure cadence — no material red flags in recent filings.
Recent filings
all on EDGAR ↗8-KPeriod ending 2026-06-172026-06-18open ↗8-KPeriod ending 2026-06-112026-06-11open ↗DEFA14AFiling2026-06-05open ↗10-QPeriod ending 2026-03-312026-05-07open ↗8-KPeriod ending 2026-05-072026-05-07open ↗DEFR14AFiling2026-05-01open ↗ARSPeriod ending 2025-12-312026-04-24open ↗DEFA14AFiling2026-04-24open ↗DEF 14APeriod ending 2025-12-312026-04-24open ↗PRE 14APeriod ending 2025-12-312026-04-10open ↗8-KPeriod ending 2026-03-312026-03-31open ↗S-8Filing2026-03-05open ↗
Frequently asked
- Is Caribou Biosciences, Inc. (CRBU) a buy?
- CRBU currently carries a Sell rating with 2/5 conviction, derived from its latest SEC filings. Revenue grew 11.7% YoY; but unprofitable (net margin -1327.4%).
- What is Caribou Biosciences, Inc.'s quality score?
- CRBU scores 44.80392156862745/100 (grade D) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001619856, latest 10-Q filed 2026-05-07) · EODHD · as of 6/26/2026, 6:08:46 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.